InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by Dexter Susan, Chief Technology Officer. Officer active across 1 companies, notably Sonnet BioTherapeutics Holdings, Inc.. Cumulatively, 3 reports have been published. The latest transaction was disclosed on 25 May 2021 (Retenue fiscale). Regulator: SEC (Form 4). The full history is free.
Declarations3 total
63,104 shares
Common Stock
SEC:0001493152-22-009481:0·
€12,50610,145 shares@ €1.2327100.0% of flow
Common Stock
SEC:0001493152-21-013203·
€12,50610,145 shares@ €1.232750.0% of flow
Common Stock
SEC:0001493152-21-013203:0·
3 of 3 declarations
About Dexter Susan
Susan Dexter is the Chief Technical Officer at Sonnet BioTherapeutics Holdings, Inc. She is responsible for the company's technological initiatives, ensuring innovation and efficiency in processes. Her expertise in the biopharmaceutical field is crucial for the development of new therapies.
